GW Pharmaceuticals Buy Hold or Sell Recommendation

GWPH -- USA Stock  

USD 113.23  2.20  1.98%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding GW Pharmaceuticals Plc is 'Cautious Hold'. Macroaxis provides GW Pharmaceuticals buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding GWPH positions. The advice algorithm takes into account all of GW Pharmaceuticals Plc available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from GWPH buy-and-hold prospective. Please also check GW Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Symbol
Execute Advice
Sell GW PharmaceuticalsBuy GW Pharmaceuticals
Cautious Hold

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

Inapplicable
For the selected time horizon GW Pharmaceuticals Plc has a mean deviation of 3.33, semi deviation of 0.0, standard deviation of 5.99, variance of 35.83, downside variance of 0.0 and semi variance of 0.0
Macroaxis provides buy or sell advice on GW Pharmaceuticals Plc to complement and cross-verify current analyst consensus on GW Pharmaceuticals. Our buy, hold, or sell suggestion engine determines the entity potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. To make sure GW Pharmaceuticals Plc is not overpriced, please check out all GW Pharmaceuticals Plc fundamentals including its Net Income, Price to Earnings To Growth and the relationship between Price to Book and Current Ratio . Given that GW Pharmaceuticals Plc has Number of Shares Shorted of 5.12 M, we strongly advise you confirm GW Pharmaceuticals market performance and probability of bankruptcy to make sure the company can sustain itself this quarter and beyond given your latest risk tolerance and investing horizon.

GW Pharmaceuticals Trading Alerts and Improvement Suggestions

GW Pharmaceuticals generates negative expected return over the last 30 days
GW Pharmaceuticals has high historical volatility and very poor performance
The company reported previous year revenue of 131.58 M. Net Loss for the year was (104.47 M) with loss before overhead, payroll, taxes, and interest of (19.8 M).
GW Pharmaceutical currently holds about 583.68 M in cash with (289.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.9.
Over 82.0% of the company shares are owned by institutional investors
Latest headline from newsplanets.us: Facing Competition, But Still Strong - GW Pharmaceuticals plc, - News Planets

GW Pharmaceuticals current analysts recommendations

Target Median Price200.00
Target Mean Price206.93
Recommendation Mean1.70
Target High Price260.00
Number Of Analyst Opinions15
Target Low Price160.00

GW Pharmaceuticals Returns Distribution Density

Mean Return0.35Value At Risk6.32
Potential Upside5.22Standard Deviation5.99
 Return Density 
      Distribution 

GW Pharmaceuticals Greeks

α
Alpha over DOW
=0.49
β
Beta against DOW=1.62
σ
Overall volatility
=6.12
Ir
Information ratio =0.07

GW Pharmaceuticals Volatility Alert

GW Pharmaceuticals Plc exhibits very low volatility with skewness of -1.92 and kurtosis of 17.97. However, we advise investors to further study GW Pharmaceuticals Plc technical indicators to make sure all market info is available and is reliable.
    
 Better Than Average     
    
 Worse Than Average Compare GW Pharmaceuticals to competition

GW Pharmaceuticals Fundamental Vs Peers

FundamentalsGW PharmaceuticalsPeer Average
Return On Equity(0.66) (0.31) 
Return On Asset(0.57) (0.14) 
Profit Margin(0.001) (1.27) 
Operating Margin(170.54) (5.51) 
Current Valuation3.43 B16.62 B
Shares Outstanding30.89 M571.82 M
Shares Owned by Insiders0.62 10.09 
Shares Owned by Institutions81.95 39.21 
Number of Shares Shorted5.12 M4.71 M
Price to Earning(18.91) 28.72 
Price to Book5.46 9.51 
Price to Sales29.61 11.42 
Revenue131.58 M9.43 B
Gross Profit(19.8 M)27.38 B
EBITDA(214.16 M)3.9 B
Net Income(104.47 M)570.98 M
Cash and Equivalents583.68 M2.7 B
Cash per Share18.90 5.01 
Total Debt35.25 M5.32 B
Debt to Equity4.80 48.70 
Current Ratio8.31 2.16 
Book Value Per Share13.30 1.93 K
Cash Flow from Operations(289.39 M)971.22 M
Short Ratio8.14 4.00 
Earnings Per Share(3.29) 3.12 
Price to Earnings To Growth9.79 4.89 
Number of Employees79118.84 K
Beta2.28-0.15
Market Capitalization3.9 B19.03 B
Total Asset453.18 M29.47 B
Retained Earnings(475.39 M)9.33 B
Working Capital369.57 M1.48 B
Current Asset404.52 M9.34 B
   GW Pharmaceuticals exotic insider transaction detected [view details]
Search macroaxis.com